Por algún lado leí que las fechas del rally navideño las enmarcaban históricamente en la última semana del año y la primera del siguiente o también desde el 24 de diciembre hasta la llegada de los reyes. Que para el caso es lo mismo.
Edito : A modo de ejemplo http://www.megabolsa.com/2015/07/28/que-es-el-rally-de-navidad-o-de-santa-claus/
Muchas gracias , Seguidor.
MTSL Issue 817 - 17 Diciembre
http://www.bioinvest.com/wp-content/uploads/2015/12/MTSL-Issue-817.pdf
ALKS, ANTH, MDCO, NKTR, NVAX, OGXI, PCRX, SGMO, ZIOP
NVAX – Begins Phase III Maternal Trial Early – RESOLVE Trial Enrollment Complete
The first subject in the registration maternal trials for the RSV vaccine was announced last week, somewhat earlier than the Q1:16 forecast (https://clinicaltrials.gov/ct2/show/NCT02624947?term=Novavax+maternal&rank=1). The collaborator is The Bill and Melinda Gates Foundation, which awarded NVAX $89 million in funding for this trial back in September when the initial positive results were released. While the trial is expected to take 2-4 years to be completed, a big window depending on the pace of enrollment of the roughly 5,000-8,000 pregnant women, the rapid regulatory and clinical turnaround from a small Phase II 50-person (~28 on vaccine) trial is testimony to both the strong regulatory support for this vaccine and astute management execution.
Even more importantly, the Phase IIIRESOLVE trial of the RSV vaccine in the elderly has completed full enrollment of roughly 11,850 subjects at over 60 centers worldwide in just 35 days (https://clinicaltrials.gov/ct2/show/NCT02608502?term=Novavax+RSV+vaccine+elderly&rank=1) – one more example of management’s focus and execution on this soon-to-be first ever RSV vaccine. In early 2016, the Company is due to reveal strategies on three areas of company development: a) Novavax‘s quadrivalent flu vaccine; b) the disruptive quadrivalent flu/RSV combo (‘respiratory’) vaccine, and c) the RSV vaccine for pediatrics (ages 2-6). While the end prize seems far away in this stock market, NVAX continues to move as fast as possible with its breakthrough program, with Phase III data in the elderly in H2:16 and an FDA application filing and approval soon thereafter. 2015 has been the most de-risking and value added year in the Company’s history by a huge margin.
NVAX is a BUY under 15 with a TARGET PRICE of 20
Los futuros vienen en +%1 !
Ummm ... no me gusta , me mantengo al margen de tradearla
AMRN
GILD, ese gap habra que cerrarlo, digo yo ...
edito: de hecho, tenemos un timido premarket en verde a 102,37 ahora mismo que de abrirse en ese punto y luego bajar a cerrar y ya tendria el hueco tapado
ZIOP semanal
IBB Diario
Los 339 parecen ser un freno evidente en diario, por el momento.La resistencia fuerte la tendriamos por los 344
Sin embargo, en SEMANAL, los 337 para esta semana parecen ser la barrera bajista a superar
ZIOP
En diario se ve algo diferente. Yo la estoy esperando en el gap entre 6,04 - 6,65$ (que no se ve en el gráfico semanal). Ahí si tengo cash le meto casi seguro, y si rebota donde está ahora pues nada, a otra cosa...
